ManufacturingRoche's Actemra may see high demand and short supply...

Roche’s Actemra may see high demand and short supply due to COVID delta variant

-

The infused form of Genentech’s arthritis drug, tocilizumab (Roche Actemra), which is being used as a therapy for severe COVID-19 cases, is running short of supply in the U.S.  

According to the drugmaker, Roche Actemra IV’s demand ramped up during the recent COVID-19 wave caused by the highly contagious delta variant of the virus. Considering only the last two weeks, the demand for the drug took flight to reach up to 400% as compared to the pre-COVID days, and is still increasing.

The U.S. Food and Drug Administration, in June, issued an emergency use authorization (EUA) of Actemra IV only for the treatment of COVID patients. Unfortunately, the 200 mg and 400 mg dose formulations of the drug are already out of stock in the United States for the time being, and now it is running out of the 80 mg dose supply as well, said the biotech.

However, Roche Actemra injectable form that is solely used as a therapy for arthritis and other inflammatory-related conditions, are still available in the market, it further added.

The end of this month awaits further shipments of the drug. Roche Actemra subsidiary, Genentech, stated, “However, if the pandemic continues to spread at its current pace, we anticipate additional periods of stockout in the weeks and months ahead.”

The FDA said that the infused form of the drug is being used as a therapy for COVID-stricken people who are receiving systemic corticosteroids and need supplemental oxygen, extracorporeal membrane oxygenation or mechanical ventilation. Hence, it is only authorized for the hospitalized patients and not the outpatients.  

Life Sciences Voice Logo mobile
+ posts

Latest news

Phase 3 of Merck and Moderna’s customized cancer vaccine lowers recurrence, paving the way for approval

Key Trial Breakthrough in Skin Cancer The personalized mRNA cancer vaccine developed by Merck & Co. and Moderna has proven...

FDA Issues Warning Letters to Aurobindo’s Eugia Unit and Tianjin Kilo Pharmaceutical

The U.S. Food and Drug Administration (FDA) has issued warning letters to Aurobindo Pharma’s sterile injectables and oncology subsidiary...

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Novo Nordisk has started a new late-stage clinical study to evaluate lower maintenance doses of its oral obesity treatment...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you